vs
Fortress Biotech, Inc.（FBIO）与PCB BANCORP（PCB）财务数据对比。点击上方公司名可切换其他公司
PCB BANCORP的季度营收约是Fortress Biotech, Inc.的1.8倍（$29.2M vs $16.1M），PCB BANCORP同比增速更快（11.3% vs 6.3%），过去两年Fortress Biotech, Inc.的营收复合增速更高（11.0% vs 10.4%）
堡垒生物科技（Fortress Biotech）是一家生物制药企业，核心业务为收购、开发并商业化创新医药与生物技术产品。公司由医学博士林赛·A·罗森瓦尔德担任首席执行官，包括绝大多数子公司在内，公司总部均设于佛罗里达州贝港群岛。
PCB BANCORP旗下的PCB银行是一家总部位于加利福尼亚州的美国社区银行，主要服务韩裔美国社群，提供商业银行服务，目前在全美8个州设有分支机构，规模在韩资背景美国银行中位列第三，仅次于希望银行与韩美银行。
FBIO vs PCB — 直观对比
营收规模更大
PCB
是对方的1.8倍
$16.1M
营收增速更快
PCB
高出5.1%
6.3%
两年增速更快
FBIO
近两年复合增速
10.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $29.2M |
| 净利润 | $-3.9M | — |
| 毛利率 | 66.1% | — |
| 营业利润率 | -28.8% | 45.0% |
| 净利率 | -24.5% | — |
| 营收同比 | 6.3% | 11.3% |
| 净利润同比 | 41.8% | — |
| 每股收益（稀释后） | $-0.15 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FBIOPCB
| Q4 25 | $16.1M | $29.2M | ||
| Q3 25 | $17.6M | $30.4M | ||
| Q2 25 | $16.4M | $29.3M | ||
| Q1 25 | $13.1M | $26.9M | ||
| Q4 24 | $15.1M | $26.2M | ||
| Q3 24 | $14.6M | $25.3M | ||
| Q2 24 | $14.9M | $24.2M | ||
| Q1 24 | $13.0M | $23.9M |
净利润FBIOPCB
| Q4 25 | $-3.9M | — | ||
| Q3 25 | $5.8M | $11.4M | ||
| Q2 25 | $15.5M | $9.1M | ||
| Q1 25 | $-10.6M | $7.7M | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | $-12.9M | $7.8M | ||
| Q2 24 | $-10.9M | $6.3M | ||
| Q1 24 | $-15.4M | $4.7M |
毛利率FBIOPCB
| Q4 25 | 66.1% | — | ||
| Q3 25 | 67.4% | — | ||
| Q2 25 | 69.9% | — | ||
| Q1 25 | 63.5% | — | ||
| Q4 24 | 69.1% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 61.6% | — | ||
| Q1 24 | 53.9% | — |
营业利润率FBIOPCB
| Q4 25 | -28.8% | 45.0% | ||
| Q3 25 | -38.6% | 52.3% | ||
| Q2 25 | -222.2% | 43.3% | ||
| Q1 25 | -169.9% | 40.2% | ||
| Q4 24 | -158.3% | 39.3% | ||
| Q3 24 | -151.0% | 42.2% | ||
| Q2 24 | -186.5% | 36.3% | ||
| Q1 24 | -280.6% | 27.2% |
净利率FBIOPCB
| Q4 25 | -24.5% | — | ||
| Q3 25 | 33.2% | 37.5% | ||
| Q2 25 | 94.4% | 31.0% | ||
| Q1 25 | -80.6% | 28.8% | ||
| Q4 24 | -44.7% | — | ||
| Q3 24 | -88.0% | 30.8% | ||
| Q2 24 | -73.5% | 25.9% | ||
| Q1 24 | -118.3% | 19.6% |
每股收益（稀释后）FBIOPCB
| Q4 25 | $-0.15 | $0.65 | ||
| Q3 25 | $0.11 | $0.78 | ||
| Q2 25 | $0.45 | $0.62 | ||
| Q1 25 | $-0.48 | $0.53 | ||
| Q4 24 | $-0.16 | $0.46 | ||
| Q3 24 | $-0.76 | $0.52 | ||
| Q2 24 | $-0.73 | $0.43 | ||
| Q1 24 | $-1.04 | $0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $79.4M | $207.1M |
| 总债务越低越好 | $52.4M | — |
| 股东权益账面价值 | $49.9M | $390.0M |
| 总资产 | $185.5M | $3.3B |
| 负债/权益比越低杠杆越低 | 1.05× | — |
8季度趋势，按日历期对齐
现金及短期投资FBIOPCB
| Q4 25 | $79.4M | $207.1M | ||
| Q3 25 | $86.2M | $369.5M | ||
| Q2 25 | $74.4M | $263.6M | ||
| Q1 25 | $91.3M | $214.3M | ||
| Q4 24 | $57.3M | $198.8M | ||
| Q3 24 | $58.9M | $193.1M | ||
| Q2 24 | $76.2M | $177.6M | ||
| Q1 24 | $83.8M | $239.8M |
总债务FBIOPCB
| Q4 25 | $52.4M | — | ||
| Q3 25 | $47.8M | — | ||
| Q2 25 | $50.0M | — | ||
| Q1 25 | $56.4M | — | ||
| Q4 24 | $58.0M | — | ||
| Q3 24 | $52.5M | — | ||
| Q2 24 | $67.0M | — | ||
| Q1 24 | $61.4M | — |
股东权益FBIOPCB
| Q4 25 | $49.9M | $390.0M | ||
| Q3 25 | $55.9M | $384.5M | ||
| Q2 25 | $43.9M | $376.5M | ||
| Q1 25 | $22.3M | $370.9M | ||
| Q4 24 | $22.7M | $363.8M | ||
| Q3 24 | $21.2M | $362.3M | ||
| Q2 24 | $17.9M | $353.5M | ||
| Q1 24 | $23.0M | $350.0M |
总资产FBIOPCB
| Q4 25 | $185.5M | $3.3B | ||
| Q3 25 | $181.4M | $3.4B | ||
| Q2 25 | $159.9M | $3.3B | ||
| Q1 25 | $178.1M | $3.2B | ||
| Q4 24 | $144.2M | $3.1B | ||
| Q3 24 | $127.1M | $2.9B | ||
| Q2 24 | $145.7M | $2.9B | ||
| Q1 24 | $164.6M | $2.9B |
负债/权益比FBIOPCB
| Q4 25 | 1.05× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 2.53× | — | ||
| Q4 24 | 2.55× | — | ||
| Q3 24 | 2.48× | — | ||
| Q2 24 | 3.75× | — | ||
| Q1 24 | 2.67× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-12.5M | $26.6M |
| 自由现金流经营现金流 - 资本支出 | — | $24.4M |
| 自由现金流率自由现金流/营收 | — | 83.6% |
| 资本支出强度资本支出/营收 | — | 7.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $46.0M |
8季度趋势，按日历期对齐
经营现金流FBIOPCB
| Q4 25 | $-12.5M | $26.6M | ||
| Q3 25 | $-6.1M | $16.4M | ||
| Q2 25 | $-27.6M | $4.9M | ||
| Q1 25 | $-19.6M | $2.3M | ||
| Q4 24 | $-12.9M | $39.0M | ||
| Q3 24 | $-20.1M | $11.9M | ||
| Q2 24 | $-21.8M | $14.6M | ||
| Q1 24 | $-25.4M | $8.2M |
自由现金流FBIOPCB
| Q4 25 | — | $24.4M | ||
| Q3 25 | — | $16.2M | ||
| Q2 25 | — | $3.8M | ||
| Q1 25 | — | $1.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | — | $11.9M | ||
| Q2 24 | — | $12.8M | ||
| Q1 24 | — | $6.0M |
自由现金流率FBIOPCB
| Q4 25 | — | 83.6% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 13.1% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | — | 133.2% | ||
| Q3 24 | — | 46.8% | ||
| Q2 24 | — | 53.1% | ||
| Q1 24 | — | 25.2% |
资本支出强度FBIOPCB
| Q4 25 | — | 7.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 3.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | 15.5% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | — | 7.3% | ||
| Q1 24 | — | 9.3% |
现金转化率FBIOPCB
| Q4 25 | — | — | ||
| Q3 25 | -1.04× | 1.44× | ||
| Q2 25 | -1.78× | 0.54× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.52× | ||
| Q2 24 | — | 2.33× | ||
| Q1 24 | — | 1.76× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
